Your browser is no longer supported. Please, upgrade your browser.
ARPO Aerpio Pharmaceuticals, Inc. daily Stock Chart
Aerpio Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.46 Insider Own24.32% Shs Outstand40.59M Perf Week0.00%
Market Cap53.60M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float32.96M Perf Month3.28%
Income-18.70M PEG- EPS next Q- Inst Own24.50% Short Float0.86% Perf Quarter129.09%
Sales- P/S- EPS this Y-87.10% Inst Trans- Short Ratio0.12 Perf Half Y99.21%
Book/sh0.81 P/B1.56 EPS next Y- ROA-43.80% Target Price1.00 Perf Year55.56%
Cash/sh0.81 P/C1.55 EPS next 5Y- ROE-47.60% 52W Range0.42 - 1.53 Perf YTD102.09%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-17.65% Beta-
Dividend %- Quick Ratio13.30 Sales past 5Y- Gross Margin- 52W Low200.00% ATR0.09
Employees12 Current Ratio13.30 Sales Q/Q- Oper. Margin- RSI (14)59.00 Volatility6.28% 7.45%
OptionableNo Debt/Eq0.00 EPS Q/Q53.90% Profit Margin- Rel Volume0.18 Prev Close1.32
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.30M Price1.26
Recom3.00 SMA20-0.12% SMA5023.57% SMA20080.19% Volume407,622 Change-4.55%
Jul-23-18Initiated Needham Buy $10
Jun-29-20 05:50PM  
Jun-24-20 08:00AM  
Jun-22-20 07:24AM  
Jun-19-20 05:45PM  
Jun-15-20 10:07AM  
Jun-12-20 11:30AM  
Jun-08-20 04:44PM  
Jun-05-20 08:46AM  
May-29-20 09:59AM  
May-27-20 04:30PM  
May-26-20 07:49AM  
May-21-20 12:00PM  
May-13-20 07:40AM  
May-12-20 04:30PM  
May-11-20 11:30AM  
May-07-20 08:00AM  
May-06-20 05:45PM  
Apr-24-20 07:24AM  
Apr-22-20 05:50PM  
Apr-20-20 10:46AM  
Apr-16-20 08:39AM  
Apr-09-20 06:35AM  
Apr-08-20 12:00PM  
Mar-16-20 08:00AM  
Mar-12-20 05:00PM  
Feb-09-20 09:49AM  
Feb-07-20 06:20PM  
Jan-08-20 08:43AM  
Dec-22-19 05:08PM  
Nov-11-19 06:59AM  
Nov-07-19 07:00AM  
Oct-21-19 11:09AM  
Oct-10-19 02:30PM  
Oct-09-19 09:00AM  
Aug-14-19 04:59PM  
Aug-08-19 07:00AM  
Jul-05-19 01:09PM  
Jun-10-19 07:00AM  
May-14-19 12:36PM  
May-09-19 07:00AM  
May-02-19 07:00AM  
Apr-25-19 07:00AM  
Apr-09-19 09:00AM  
Apr-05-19 04:05PM  
Mar-18-19 03:05PM  
Mar-07-19 06:48AM  
Mar-05-19 07:00AM  
Feb-26-19 07:00AM  
Jan-22-19 08:39AM  
Jan-17-19 07:00AM  
Nov-28-18 04:31PM  
Nov-14-18 07:30AM  
Nov-08-18 07:00AM  
Nov-07-18 07:00AM  
Oct-31-18 07:00AM  
Oct-25-18 08:00AM  
Sep-24-18 07:00AM  
Aug-30-18 07:00AM  
Aug-16-18 09:37AM  
Aug-14-18 07:00AM  
Aug-07-18 07:00AM  
Jul-23-18 07:24PM  
Jun-26-18 09:18AM  
Jun-25-18 04:01PM  
May-31-18 07:00AM  
May-22-18 08:52AM  
May-15-18 06:15PM  
May-04-18 11:30AM  
Apr-21-18 04:58PM  
Mar-20-18 07:10AM  
Mar-15-18 07:00AM  
Mar-13-18 07:00AM  
Mar-07-18 07:00AM  
Mar-06-18 07:00AM  
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds for the treatment of ocular diseases and diabetic complications. The company's lead product candidate is razuprotafib, a small molecule activator of the Tie2 pathway, which completed the Phase IIb clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which is in a Phase 1b clinical trial for the treatment of inflammatory bowel disease; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a collaboration with Quantum Leap Healthcare Collaborative for the evaluation of razuprotafib in the treatment of acute respiratory distress syndrome in adult patients with moderate to severe COVID-19. The company is headquartered in Cincinnati, Ohio.